IJR News - today's news from every side
block
verse
w
o
rdys
billionaire
.ai
your
list
Whiteboard
App
quizie
un
school
New Journal
Loading
Genius — OpenServe
News
Home
Popular
Congress
Genius — OpenServe
Trending
Roche to Present Evidence on Blood Tests for Alzheimer’s Amyloid
Health
— Nov 9, 2026
Roche and Genentech will present Alzheimer’s drug and blood-diagnostic research at CTAD 2026, including a new Phase II trial of an investigational drug targeting neuroinflammation. Other reports highlight research on blood biomarkers and the potential of FDA-cleared blood testing to help diagnose Alzheimer’s less invasively, while emphasizing that tests must be interpreted alongside other assessments.
+3
+1
1
Share
Jared Kim
Blood tests sound promising for catching Alzheimer's earlier without invasive procedures, but they still need careful interpretation with other data.
Hanmi Genentech obesity drug deal worth $2.3B reported
Genentech
— Aug 24, 2026
Hanmi Pharmaceutical has signed an exclusive, worldwide license with Genentech for HM17321, a long-acting UCN2 analog aimed at obesity that promises weight loss with muscle preservation, with Genentech taking over development from Phase 2 onward outside Korea. The deal could reach about $2.3 billion, including a $190 million upfront, up to $2.1 billion in milestones, and future royalties, subject to U.S. antitrust clearance and successful clinical progression.
+11
0
Share
Genentech-DualityBio Global ADC Deal Over $1B
Business
— Aug 28, 2026
DualityBio and Genentech (Roche) have launched a global collaboration to develop next-generation antibody-drug conjugates using the DUPAC payload platform, featuring a $45 million upfront and potential milestones exceeding $1 billion, with DualityBio leading early discovery and Genentech obtaining exclusive worldwide rights after Phase 1a. The program targets tumors resistant to current topoisomerase-inhibitor–based ADCs, backed by preclinical data and potential expansion into China via the Dupac platform.
+4
0
Share
BioNTech and Roche to present new cancer drug data at ESMO 2026
Hoffmann-La Roche
— Oct 19, 2026
BioNTech plans to present 16 oncology abstracts at ESMO 2026, including Phase 2 data on pumitamig combinations in advanced cancers and a trial of pumitamig plus docetaxel for metastatic lung cancer. Roche’s Genentech will present late-stage findings on divarasib in KRAS G12C-mutated lung cancer, giredestrant in breast cancer and its experimental Tam-Peli therapy.
+4
+2
2
Share
Rachel Meyers
Roche's work on divarasib in KRAS G12C cases might finally give mutation-specific lung cancer patients better odds.
IJR
GOP Megadonor’s Company Reportedly Donated To Dem Attorney General Who Openly Floated Killings Of Republican Colleague’s Children
Spencer Lombardo · 3 min · 3h
BioNTech halts Phase 2 cancer vaccine trial
Health
— Aug 28, 2026
BioNTech and Genentech/Roche have terminated the Phase 2 trial of autogene cevumeran for ctDNA-positive, surgically resected high-risk colorectal cancer after an independent DSMB cited a numerical survival imbalance, with further continuation deemed unlikely to change outcomes. The company will analyze the data to refine patient selection, and a separate Phase 2 trial in pancreatic cancer remains ongoing.
+9
0
Share
Most Influential Women in World History
Yourlist
— Ranking
From ancient queens who ruled empires to modern activists who changed laws, these women left indelible marks on politics, science, and culture. Vote for who you think shaped history most profoundly.
Share